Announced Thu, 16 Jul · 08:42 IST
Biocon Malaysia Gets EMA Approval for Insulin Fill-Finish Unit
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.5%1-day move
₹434.35
prior close
₹438.40
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.7-0.7-0.8-0.1+0.5+0.4+1.4+0.9+0.6+0.6————
Up moveDown movePending
AI summary
Biocon's Malaysia facility received EMA approval for a new drug product fill finish line for Semglee (insulin glargine). Supplies to Europe from this new line are expected to start from Q2FY27. This expands Biocon's insulin manufacturing capacity and enables exports of its biosimilar insulin to European markets.
Likely market impact
Positive: new EMA-approved capacity supports European supply of Semglee from Q2FY27, aiding insulin business revenue growth.